Pharmaceutical

Global Biopharma Layoffs February 2026 Layoffs Layoff GSK BMS Global Biopharma companies including GSK, IO Biotech, and Bitterroot Bio announce workforce reductions in February 2026 as part of cost-saving and strategic realignments, impacting research, technology, and leadership roles across their operations.
Global Biopharma Layoffs January 2026 Layoffs Layoff Takeda Gilead This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs December 2025 Layoffs Layoff Pfizer This article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs November 2025 Layoffs Layoff Novatis AbbVie Bayer Merck This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs October 2025 Layoffs Layoff Novo Nordisk Takeda GSK This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs September 2025 Layoffs Layoff Novartis Merck Novo Nordisk The biopharmaceutical industry sees major september layoffs, with companies like Novartis cutting jobs amid restructurings, trial setbacks, and M&A activity.
Henlius Biotech H1 2025 Financial Report Henlius Biotech Biotech Chinese Pharmaceutical Market Financial statements Henlius reports H1 2025 results: overseas profits soar 200%, global product expansion, and innovation pipeline growth, driving ‘Globalization 2.0’ and next-gen therapies worldwide.
Hansoh Pharma H1 2025 Financial Report Hansoh Pharma Chinese Pharmaceutical Market Financial statements Hansoh Pharma’s 2025 interim report highlights strong growth, innovation-driven transformation, and a robust global pipeline, setting a new benchmark for Chinese biopharma.
Hengrui H1 2025 Financial Report Hengrui Pharmaceuticals Hengrui Financial statements Chinese Pharmaceutical Market Hengrui Medicine’s 2025 half-year report shows 60% revenue from innovative drugs and $12B potential overseas deals, highlighting strong growth, R&D depth, and global expansion.
Rongchang Biopharma H1 2025 Financial Report Rongchang Biopharma Chinese Pharmaceutical Market Financial statements Rongchang Biopharma’s 2025 interim report shows 48% revenue growth, rising margins, reduced losses, and accelerated global BD deals, highlighting strong R&D, commercialization, and international expansion momentum.

< Pre 1...37 38 394041 42 43...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles